Henry Ford Hospital
Detroit, Michigan, 48202, United States
Location status: Recruiting
NCT Number: NCT04886726
So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic GVHD, progression-free survival , and overall survival
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Phase 1
Detroit, Michigan, 48202, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant
Time frame: day+30 post SCT
The maximum tolerated dose
Time frame: day+30 post SCT
The overall incidence and severity of DLTs for uhCG/EGF
Time frame: till day +100 post SCT
Cumulative incidence of acute GVHD
Time frame: one year post SCT
Cumulative incidence of chronic GVHD
Time frame: one year post SCT
Death from any cause will be considered an event. Surviving patients will be censored at the time of last follow up.
Time frame: one year
Survival following allogeneic SCT without relapse or progression. Relapse or progression of disease, or death are considered events
Contact information is provided by the study sponsor or research team.
Henry Ford Health System
Other
Post-transplant Cyclophosphamide and Urinary-derived Human Chorionic Gonadotropin and Epidermal Growth Factor (uhCG/EGF) as Graft Versus Host Disease Prophylaxis for Mismatched Unrelated Donor Transplantation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07235501
Graft Versus Host Disease, Graft vs Host Disease
Duarte, California, United States
View Trial DetailsNCT07689630
Graft Versus Host Disease, Graft vs Host Disease
Wuhan, Hubei, China
View Trial DetailsNCT06996119
Acute Myeloid Leukemia, Bone Marrow Diseases
Duarte, California, United States
View Trial DetailsNCT06815003
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Duarte, California, United States
View Trial Details